A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma

被引:13
|
作者
Iacuzzi, Valentina [1 ]
Zanchetta, Martina [1 ,2 ]
Gagno, Sara [1 ]
Poetto, Ariana Soledad [1 ,3 ]
Orleni, Marco [1 ]
Marangon, Elena [1 ]
Guardascione, Michela [1 ]
Foltran, Luisa [4 ]
Posocco, Bianca [1 ]
Toffoli, Giuseppe [1 ]
机构
[1] Ctr Riferimento Oncol Aviano CRO IRCCS, Expt & Clin Pharmacol Unit, Via F Gallini 2, I-33081 Aviano, Italy
[2] Univ Trieste, Dept Chem & Pharmaceut Sci, Via Licio Giorgieri 1, I-34127 Trieste, Italy
[3] Univ Padua, Doctoral Sch Pharmacol Sci, Lgo Meneghetti 2, I-35131 Padua, Italy
[4] Ctr Riferimento Oncol Aviano CRO IRCCS, Dept Med Oncol, Via F Gallini 2, I-33081 Aviano, Italy
关键词
LC-MS/MS; Sorafenib; Regorafenib; Therapeutic drug monitoring; Hepatocellular carcinoma; TYROSINE KINASE INHIBITORS; HUMAN PLASMA; ASSAY;
D O I
10.1016/j.jpba.2020.113358
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous quantification of sorafenib (SORA), its N-oxide active metabolite and of regorafenib (REGO) and its two active metabolites regorafenib N-oxide and N-desmethyl regorafenib N-oxide in hepatocellular carcinoma patients' plasma. A proper analytes' separation was obtained with Synergi Fusion RP column (4 mu m, 80 angstrom, 50 x 2.0 mm) using a gradient elution of 10 mM ammonium acetate with 0.1% formic acid (mobile phase A) and methanol:isopropanol (90:10, v/v, mobile phase B) containing 0.1% formic acid. The analysis was then performed by electrospray ionization in negative mode coupled with a triple quadrupole mass spectrometry, API 4000QT, monitoring two transitions for each analyte, one for the quantification and the other for confirmation. The method could be easily applied to the clinical practice thanks to the short run (7 min), the low amount of patient plasma necessary for the analysis (5 mu L) and the fast sample processing based on protein precipitation. The method was therefore fully validated according to FDA and EMA guidelines. The linearity was assessed (R-2 >= 0.998) over the concentration ranges of 50-8000 ng/mL for SORA and REGO, and 30-4000 ng/mL for their metabolites, that appropriately cover the therapeutic plasma concentrations. The presented method also showed adequate results in terms of intra- and inter-day accuracy and precision (CV <= 7.2% and accuracy between 89.4% and 108.8%), recovery (>= 85.5%), sensitivity, analytes stability under various conditions and the absence of the matrix effect. Once the validation was successfully completed, the method was applied to perform the C-min quantification of SORA, REGO and their metabolites in 54 plasma samples collected from patients enrolled in a clinical study ongoing at the National Cancer Institute of Aviano. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Some thoughts on the links between LC-MS/MS and therapeutic drug monitoring
    Saint-Marcoux, Franck
    ANNALES DE BIOLOGIE CLINIQUE, 2015, 73 (01) : 49 - 53
  • [22] A simple dried blood spot method for therapeutic drug monitoring of the tricyclic antidepressants amitriptyline, nortriptyline, imipramine, clomipramine, and their active metabolites using LC-MS/MS
    Berm, E. J. J.
    Paardekooper, J.
    Brummel-Mulder, E.
    Hak, E.
    Wilffert, B.
    Maring, J. G.
    TALANTA, 2015, 134 : 165 - 172
  • [23] A Validated LC-MS/MS Method for the Determination of Mezlocillin in Plasma: An Adapted Method for Therapeutic Drug Monitoring in Children
    Tang, Bo-Hao
    Kan, Min
    Yang, Xin-Mei
    Wang, Rong-Hua
    Shi, Hai-Yan
    Zheng, Yi
    Hao, Guo-Xiang
    Song, Lin-Lin
    Zhao, Wei
    CURRENT PHARMACEUTICAL ANALYSIS, 2021, 17 (07) : 853 - 860
  • [24] Comparison of LC-MS/MS and Nanoparticle Immunoassay Method for Paclitaxel Determination Applied in Therapeutic Drug Monitoring
    Geng, Chunmei
    Li, Pingli
    Chen, Xuwang
    Gao, Meimei
    Zhang, Rui
    Kan, Zhihui
    Shaikh, Abdul S.
    Bu, Fanlong
    Guo, Ruichen
    LATIN AMERICAN JOURNAL OF PHARMACY, 2017, 36 (07): : 1316 - 1321
  • [25] Rapid method for monitoring muscle protein metabolites by LC-MS
    Auell, Olivia
    Hayes, Benjamin
    Chow, Caroline
    King, Daniel
    Hammond, D. G.
    FASEB JOURNAL, 2012, 26
  • [26] LC-MS application for therapeutic drug monitoring in alternative matrices
    Avataneo, Valeria
    D'Avolio, Antonio
    Cusato, Jessica
    Cantu, Marco
    De Nicolo, Amedeo
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 166 : 40 - 51
  • [27] Therapeutic drug monitoring of antiretroviral drugs using LC-MS
    Gutteck-Amster, Ursula
    Rentsch, Katharina M.
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 468 - 468
  • [28] Simultaneous Quantification of Nine Antimicrobials by LC-MS/MS for Therapeutic Drug Monitoring in Critically Ill Patients
    Neugebauer, Sophie
    Wichmann, Christina
    Bremer-Streck, Sibylle
    Hagel, Stefan
    Kiehntopf, Michael
    THERAPEUTIC DRUG MONITORING, 2019, 41 (01) : 29 - 37
  • [29] Potential pitfalls in LC-MS/MS quantification of colistin for therapeutic drug monitoring of patients treated with colistimethate
    Barco, Sebastiano
    Castagnola, Elio
    Mesini, Alessio
    Tripodi, Gino
    Cangemi, Giuliana
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 170 : 193 - 195
  • [30] LC-MS/MS monitoring of the colorectal carcinoma cellular uptake and entrapment of sorafenib and its N-oxide active metabolite
    Elawady, Tarek
    Al-Abd, Ahmed M.
    Khedr, Alaa
    EL-Enany, Nahed
    Belal, Fathalla
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2022, 213